|
|
Volumn 84, Issue 13, 2005, Pages 1-2
|
|
Epigenetic therapy in MDS and acute AML: Focus on decitabine
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
AZACITIDINE;
BUTYRIC ACID;
PROTEIN P15;
PROTEIN P73;
VALPROIC ACID;
BIOLOGICAL MARKER;
CYCLIN DEPENDENT KINASE INHIBITOR;
CYCLIN DEPENDENT KINASE INHIBITOR 2B;
HISTONE DEACETYLASE INHIBITOR;
UNCLASSIFIED DRUG;
ACUTE GRANULOCYTIC LEUKEMIA;
ANTINEOPLASTIC ACTIVITY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CYTOGENETICS;
DEMETHYLATION;
DOSE RESPONSE;
DRUG MEGADOSE;
DRUG TARGETING;
DRUG TOLERABILITY;
EDITORIAL;
EPIGENETICS;
GENE INDUCTION;
GENE SILENCING;
GENE THERAPY;
GENOTYPE PHENOTYPE CORRELATION;
HIGH RISK PATIENT;
HUMAN;
LOW DRUG DOSE;
MYELODYSPLASTIC SYNDROME;
OPTIMAL DRUG DOSE;
PHENOTYPE;
PRIORITY JOURNAL;
APOPTOSIS;
CHROMOSOME ABERRATION;
DRUG MECHANISM;
DRUG RESPONSE;
HEALTH CARE COST;
HEMATOLOGIC MALIGNANCY;
HOSPITALIZATION;
LENGTH OF STAY;
LEUKEMIA;
MYELODYSPLASIA;
PSYCHOSOCIAL CARE;
PUBLICATION;
RISK ASSESSMENT;
SHORT COURSE THERAPY;
TREATMENT DURATION;
UPREGULATION;
CONTROLLED CLINICAL TRIAL;
GENE EXPRESSION REGULATION;
GENE TARGETING;
PHARMACOGENETICS;
SURVIVAL TIME;
|
|
EID: 29144522144
PISSN: 09458077
EISSN: None
Source Type: Journal
DOI: 10.1007/s00277-005-0035-7 Document Type: Editorial |
|
Times cited : (7)
|
|
References (0)
|
